Últimos Artículos de Diabetes, Obesity and Metabolism
- Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study
- Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes
- Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
- A1c versus oral glucose tolerance test for chronic glycemic surveillance in women with previous gestational diabetes
- The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
- CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination
- Haemoglobin glycation index and in‐hospital mortality after acute myocardial infarction in patients with/without diabetes: A prospective, nationwide and multicentre registry
- SGLT2 inhibitors are associated with a reduced incidence of atrial fibrillation in type 2 diabetes mellitus
- Management of metabolic dysfunction–associated steatotic liver disease (MASLD)—An expert consensus statement from Indian diabetologists' perspective
- Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
- Burden of type 2 diabetes mellitus and risk factor attribution among older adults: A global, regional, and national analysis from 1990 to 2021, with projections up to 2040
- Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
- Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial
- Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and the risk of chronic kidney disease progression in patients with type 2 diabetes
- GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
- Post‐marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States: A disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) database
- Risk of new‐onset type 1 diabetes in individuals with celiac disease and thyroid disease—An observational study
- Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications
- Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia
- Fully automated insulin delivery systems in type 1 diabetes: A systematic review and meta‐analysis